Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) Starts Presentation at 30th Annual ROTH Conference
Anthera Pharmaceuticals (NASDAQ: ANTH) is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases. The company has two product candidates in development: Sollpura, a novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis; and Blisibimod, a BAFF inhibitor for the potential treatment of IgA nephropathy. For more information, visit the company’s website at www.anthera.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via…







